Literature DB >> 22699980

Outcomes of intratympanic gentamicin injection to treat Ménière's disease.

Leh-Kiong Huon1, Te-Yung Fang, Pa-Chun Wang.   

Abstract

OBJECTIVE: To investigate the outcomes of intratympanic (IT) gentamicin sulfate injection to treat intractable Ménière's disease (MD) using evidence-based methods. DATA SOURCE: Data were retrieved from a MEDLINE search (January 1995 through January 2011). STUDY SELECTION: Selected were English-language articles presenting outcomes of IT gentamicin injection to treat MD that had a prospective study design and an evidence level of II or higher. DATA EXTRACTION: The database was searched using Boolean combinations of the keywords intratympanic, gentamicin, and Ménière's disease. DATA SYNTHESIS: Dichotomous outcomes (success rate and total deafness) were expressed using a Mantel-Haenszel fixed-effects model. Pretreatment and posttreatment pure-tone audiometry results, and word discrimination scores were summarized using data synthesis techniques.
CONCLUSION: A critical literature appraisal and meta-analysis shows that IT gentamicin injection can control vertigo in patients with MD who have limited hearing injury. The quality of research in this field has improved remarkably over the years. However, a large-scale randomized controlled trial is warranted to confirm the predictive factors for the effectiveness of IT gentamicin injection in treating MD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22699980     DOI: 10.1097/MAO.0b013e318259b3b1

Source DB:  PubMed          Journal:  Otol Neurotol        ISSN: 1531-7129            Impact factor:   2.311


  17 in total

Review 1.  Menière's disease.

Authors:  Tony Wright
Journal:  BMJ Clin Evid       Date:  2015-11-05

2.  Vestibular results after intratympanic gentamicin therapy in disabling Menière's disease.

Authors:  Philippe Junet; Alexandre Karkas; Georges Dumas; Jean Louis Quesada; Sébastien Schmerber
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-01-16       Impact factor: 2.503

3.  Intratympanic gentamicin treatment 'as needed' for Meniere's disease. Long-term analysis using the Kaplan-Meier method.

Authors:  Silvia Quaglieri; Omar Gatti; Elisabetta Rebecchi; Marco Manfrin; Carmine Tinelli; Eugenio Mira; Marco Benazzo
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-06-19       Impact factor: 2.503

4.  Therapeutic illusion: another frontier in Ménière's disease.

Authors:  Nicolas Pérez-Fernández; Eduardo Martín-Sanz
Journal:  Ann Transl Med       Date:  2016-10

5.  Hearing Changes After Intratympanically Applied Steroids for Primary Therapy of Sudden Hearing Loss: A Meta-analysis Using Mathematical Simulations of Drug Delivery Protocols.

Authors:  Arne Liebau; Olivia Pogorzelski; Alec N Salt; Stefan K Plontke
Journal:  Otol Neurotol       Date:  2017-01       Impact factor: 2.311

6.  Modified titration intratympanic gentamicin injection for unilateral intractable Ménière's disease.

Authors:  Bo Liu; Yang-Ming Leng; Hong Shi; Ren-Hong Zhou; Jing-Jing Liu; Wen-Juan Zhang; Su-Lin Zhang; Wei-Jia Kong
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-10-22

7.  Intratympanic dexamethasone injections for refractory Meniere' s disease.

Authors:  Hongmiao Ren; Tuanfang Yin; Yongde Lu; Weijia Kong; Jihao Ren
Journal:  Int J Clin Exp Med       Date:  2015-04-15

Review 8.  Is gentamycin delivery via sustained-release vehicles a safe and effective treatment for refractory Meniere's disease? A critical analysis of published interventional studies.

Authors:  Petros V Vlastarakos; Emily Iacovou; Thomas P Nikolopoulos
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-09-13       Impact factor: 2.503

9.  Chemical labyrinthectomy for the worse ear of adult Nigerians with bilateral Meniere's disease: preliminary report of treatment outcomes.

Authors:  A D Olusesi; S B Hassan; Y Oyeyipo; U C Ukwuije; O Oyeniran
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-02-26       Impact factor: 2.503

10.  Intratympanic Therapies for Menière's disease.

Authors:  Matthew W Miller; Yuri Agrawal
Journal:  Curr Otorhinolaryngol Rep       Date:  2014-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.